Biotech News
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures High patient and investigator enthusiasm continues with additional participants